Cosmos Health Advances Its Technology-Driven Transformation with an AI-Enabled Subscription Platform Across B2C and B2B Channels
Rhea-AI Summary
Cosmos Health (NASDAQ:COSM) announced the active development of a flexible, technology-driven digital subscription platform to unify its proprietary consumer health products across both B2C and B2B channels. Customers will be able to start via a free nutritionist consultation, an AI-powered assistant, or by building their own package.
The platform is being designed to support consumer subscriptions at chosen frequencies, corporate subscriptions for employee wellness and gifting with multi-recipient tools, tiered pricing, centralized billing, and one-time or gift purchases. According to Cosmos Health, the initiative builds on its U.S. NOOR Collagen subscription model, which has achieved an early repeat purchase rate above 60%, and is intended to scale into international markets and support a recurring-revenue business model.
Positive
- NOOR Collagen subscription shows early repeat purchase rate above 60%
- Planned platform spans B2C and B2B with subscriptions and one-time purchases
- Corporate offering to include tiered volume pricing and centralized billing
- Strategy targets scalable, technology-enabled, recurring-revenue model
Negative
- None.
Key Figures
Previous AI Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jun 23 | AI call center | Positive | -0.6% | AI-powered call center agreement targeted order intake and customer communications |
| Jun 18 | Q2 revenue and AI | Positive | -11.9% | Record CosmoFarm revenue accompanied AI automation and facility expansion |
| Jun 10 | AI strategy update | Positive | +2.1% | Shareholder letter detailed AI strategy, revenue growth, and international expansion |
| Apr 16 | AI investment expansion | Positive | +4.0% | Expanded AI integration targeted efficiency, cost reduction, customer experience, and sales growth |
| Sep 29 | AI transformation letter | Positive | -0.9% | CEO letter outlined AI innovation, digital financing, manufacturing, and business expansion |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-tagged announcements produced mixed reactions: 3 of 5 diverged from positive disclosure sentiment, and the average 24-hour move was -1.46%.
Key Terms
b2c financial
b2b financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
- Digital subscription platform brings together the Company’s proprietary consumer health products across consumer (B2C) and corporate (B2B) channels
- Customers can begin through one of three paths: a free nutritionist consultation, an AI-powered assistant, or building their own package
- Corporate offering supports employee wellness programs and corporate gifting through multi-recipient management, tiered volume pricing, centralized billing, and dedicated account management
- Future platform enhancements are expected to include AI-driven personalization and the potential integration of at-home testing and diagnostic kits
- Platform builds on the U.S. subscription launch of NOOR Collagen, which has delivered an early repeat purchase rate above
60%
CHICAGO, July 27, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company”) (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced that it is actively developing a flexible, technology-driven subscription platform for its consumer health products, representing a significant step in the Company’s broader technology-driven transformation.
Designed around customer choice, the platform will allow customers to begin with a free consultation with a nutritionist, engage with an AI-powered assistant, or select products and build their own package. Based on each customer’s health and wellness goals, the platform will assemble a personalized package consisting primarily of Cosmos Health’s proprietary products, supplemented where appropriate with third-party products to address broader customer needs.
The platform is being designed to support multiple purchasing models, including consumer subscriptions (B2C) at the customer’s preferred frequency; corporate subscriptions (B2B) for employee wellness programs and corporate gifting, with multi-recipient management, tiered volume pricing, centralized billing, and dedicated account management; and one-time or gift purchases that may convert into ongoing subscriptions.
Recurring and one-time payments are expected to be processed through a secure, integrated checkout, with invoicing available for corporate accounts.
Over time, the Company intends to enhance the platform with AI-driven personalization that refines recommendations based on customer data and preferences. Cosmos Health also plans to explore the integration of at-home testing and diagnostic kits, which could allow subscriptions to be informed by individualized health insights.
The platform builds on the subscription model launched in the United States with NOOR Collagen, which has delivered encouraging early results, including a repeat purchase rate above
Greg Siokas, CEO of Cosmos Health, stated: "We are building a subscription platform designed to meet customers wherever they are—whether they are individual consumers, corporate clients, or one-time buyers—and turn each interaction into a lasting relationship. By combining personalized guidance with technology, and over time AI-driven personalization and diagnostic insights, we intend to deliver a differentiated consumer health experience while building the predictable, recurring revenue that creates long-term value for our shareholders.”
About Cosmos Health Inc.
Cosmos Health Inc. (Nasdaq:COSM), incorporated in 2009 in Nevada, is a diversified, vertically integrated global healthcare group. The Company owns a portfolio of proprietary pharmaceutical and nutraceutical brands, including Sky Premium Life®, Mediterranation®, bio-bebe®, C-Sept® and C-Scrub®. Through its subsidiary Cana Laboratories S.A., licensed under European Good Manufacturing Practices (GMP) and certified by the European Medicines Agency (EMA), it manufactures pharmaceuticals, food supplements, cosmetics, biocides, and medical devices within the European Union. Cosmos Health also distributes a broad line of pharmaceuticals and parapharmaceuticals, including branded generics and OTC medications, to retail pharmacies and wholesale distributors through its subsidiaries in Greece and the UK. Furthermore, the Company has established R&D partnerships targeting major health disorders such as obesity, diabetes, and cancer, enhanced by artificial intelligence drug repurposing technologies, and focuses on the R&D of novel patented nutraceuticals, specialized root extracts, proprietary complex generics, and innovative OTC products. Cosmos Health has also entered the telehealth space through the acquisition of ZipDoctor, Inc., based in Texas, USA. With a global distribution platform, the Company is currently expanding throughout Europe, Asia, and North America, and has offices and distribution centers in Thessaloniki and Athens, Greece, and in Harlow, UK. More information is available at www.cosmoshealthinc.com, www.skypremiumlife.com, www.cana.gr, www.zipdoctor.co, www.cloudscreen.gr, as well as LinkedIn and X.
Forward-Looking Statements
With the exception of the historical information contained in this news release, the matters described herein may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Words such as “believes,” “expects,” “anticipates,” “intends,” “projects,” “estimates,” “plans,” and similar expressions, or future or conditional verbs such as “will,” “should,” “would,” “may,” and “could,” generally identify forward-looking statements, although not all forward-looking statements contain these words. These statements involve risks and uncertainties that may individually or materially affect the matters discussed herein for a variety of reasons outside the Company’s control, including, but not limited to: the Company’s ability to raise sufficient financing to implement its business plan; the effectiveness of its digital asset strategies, including accumulation and yield-generating activities; the impact of the war in Ukraine and ongoing conflicts in the Middle East and other regions on the Company’s business, operations, and the economy in general; the Company’s ability to successfully develop and commercialize its proprietary products and technologies; changes in interest rates; changes in foreign currency exchange rates, commodity or other price inflation and deflation; our ability to issue debt on terms and at rates acceptable to us; the impact and expected outcome of investigations, inquiries, claims, and litigation; the challenges of operating in international markets; the adequacy of insurance coverage; the effect of accounting charges and of adopting certain accounting standards; the impact of legal and regulatory changes, including changes to tax laws and regulations; guidance for fiscal 2026 and beyond and financial outlook. Forward-looking statements are based on currently available information and our current assumptions, expectations and projections about future events. You should not rely on our forward-looking statements. These statements are not guarantees of future performance and are subject to future events, risks and uncertainties – many of which are beyond our control, dependent on the actions of third parties, or currently unknown to us – as well as potentially inaccurate assumptions that could cause actual results to differ materially from our historical experience and our expectations and projections. These risks and uncertainties include, but are not limited to, those described from time to time in our periodic reports filed with the SEC and available at the SEC’s website (www.sec.gov). There also may be other factors that we cannot anticipate or that are not described herein, generally because we do not currently perceive them to be material. Such factors could cause results to differ materially from our expectations. Forward-looking statements speak only as of the date they are made, and we do not undertake to update these statements other than as required by law. You are advised, however, to review any further disclosures we make on related subjects in our filings with the Securities and Exchange Commission and in our other public statements.
Investor Relations Contact:
BDG Communications
cosm@bdgcommunications.com
